COLORADO SPRINGS, Colo.,
Aug. 22, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, is pleased to announce its sponsorship of UFCM
iCare's third international medical cannabis conference taking
place at the Faculty of Medicine of Strasbourg, France, on October 22, 2014. The multilingual
conference brings together industry experts with other
stakeholders, such as researchers, health professionals, and
patients, to discuss the development of medical cannabis in
Europe and North America.
"Cannabis Science is delighted to contribute to the UFCM iCare
initiatives to encourage discussion and promote innovation in the
medical cannabis arena as the Company strives to move forward in
bringing cannabinoid-based medicines to patients on a global
basis," said Dorothy H. Bray, Ph.D.,
Director, President and CEO of Cannabis Science, Inc.
French law provides for a regulatory framework for the research
and development of cannabinoid-based medicine that will then be
available to patients in mainstream pharmacies. The
upcoming conference of international experts is intended to
facilitate patient-driven dialog with the researchers and with the
industry. UFCM has assembled a team of prominent speakers
including Professor Raphael
Mechoulam from the Hebrew University in
Jerusalem in Israel and
Professor Jerome Sèze from
Department of Neurology, University Hospital of Strasbourg in France. Additional information about the
conference and its speakers may be found here UFCM iCare Conference
Speakers.
About the UFCM
Founded in 2009, the UFCM is the leading medical cannabis
charity in France. Its mission is to promote medical cannabis
by developing a network of doctors, patients and lawyers in
France, organizing the primary
French conference about medical cannabis, and providing information
about medical cannabis in French. UFCM iCare Website.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.